When a dose of a Covid-19 vaccine leaves a US manufacturing plant, its path can be traced all the way to the hospital or clinic representative signing for the shipment at its destination. What happens next is not always clear. Federal agencies overseeing the rollout are relying on a tangled web of aging state vaccine registries complicated by state laws and practices. Data collection has improved since the national vaccination campaign began in December, with county-level reporting in most states. But gaps and tech issues remain that could compromise equitable distribution of doses, analysis of vaccine protection, and identification of pockets of vaccine hesitancy, experts said.
This content was originally published here.